Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Mild and Moderate Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function
Phase of Trial: Phase I
Latest Information Update: 22 Mar 2018
At a glance
- Drugs Somapacitan (Primary)
- Indications Somatotropin deficiency
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 19 Mar 2018 Status changed from active, no longer recruiting to completed.
- 06 Feb 2018 Planned End Date changed from 30 Apr 2018 to 15 Mar 2018.
- 06 Feb 2018 Status changed from recruiting to active, no longer recruiting.